Engflag

Nitrosan

Quick links to important sections

Nitrosan

Nitrosan_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitrosan

Quick Facts: Nitrosan

Property Description
Active Ingredients Nitroglycerin, Nitroscanate
Form Primarily Solid Oral Forms (Tablet/Capsule)
Pharmacological Class Vasodilator and Anthelmintic
General Purpose Circulatory Support and Parasite Management
Origin Primarily Synthetic Chemical Compounds

What Type of Medicine is Nitrosan? (Identity and Classification)

Nitrosan is a synthetic compound pharmaceutical preparation defined by the combination of two active agents belonging to fundamentally different pharmacological groups. It is structurally classified as a combination product, integrating a human cardiovascular agent with an anti-parasitic agent into a single entity. The formulation merges two distinct pharmacological classes: an Antianginal/Vasodilator agent and an Anthelmintic agent. In this context, Nitroglycerin acts as a Vasodilator. This unique combination is clinically recognized for addressing conditions that necessitate simultaneous management of vascular function and parasitic presence.

Composition and Origin: Nitroglycerin and Nitroscanate (Composition and Form Intents)

the definitive active ingredients of Nitrosan are Nitroglycerin (Glyceryl Trinitrate) and Nitroscanate (Dichlorophenoxy-methane sulfonanilide), both of which are primarily synthetic chemical compounds. This composition differentiates Nitrosan from single-entity medicines, such as those containing only Nitroglycerin for cardiovascular use. As a solid oral form, the medicine is typically manufactured as a tablet or capsule, utilizing standard pharmaceutical excipients as a non-active base for stable, systemic delivery. The presence of Nitroscanate defines the anti-parasitic component of the formulation.

General Purpose of the Dual-Action Formulation (Mechanism and Use Intents)

The general purpose of this dual-action formulation is to provide simultaneous circulatory support and management of internal biological burdens from parasites. The Nitroglycerin component functions as a Nitric Oxide (NO) donor, inducing the widespread relaxation of blood vessels to improve systemic blood flow. Concurrently, the Nitroscanate component contributes its specific anti-parasitic action. This interdisciplinary mechanism is intended to mitigate physiological stress related to circulatory resistance while addressing underlying parasitic infestations, a typical application for combined-therapy regimens.

Regulatory References

  1. NIH Drug Classification

What side effects are possible with Nitrosan?

Possible side effects and safety information

The safety profile of Nitrosan, containing a vasodilator (Nitroglycerin) and an anthelmintic (Nitroscanate), is classified by government regulatory documents based on the known effects of its components. Adverse reactions are grouped by the affected System-Organ-Class (SOC) and frequency of occurrence.

Frequency-Classified Adverse Reactions

The most frequently reported effects are generally those associated with the vasodilator component. Headache is classified as a Very Common (ge 1/10) reaction, often noticeable at the start of treatment or following a dose adjustment. Common (ge 1/100 to < 1/10) effects include dizziness, hypotension (low blood pressure), and nausea/vomiting. Less frequent effects are documented under Uncommon or Rare categories, such as Tachycardia (increased heart rate) or certain gastrointestinal disturbances.

System-Organ-Class and Serious Reactions

Adverse effects are reported across several systems, including Nervous System Disorders (headache, dizziness), Vascular Disorders (hypotension, flushing), and Gastrointestinal Disorders. The regulatory profile also documents rare but clinically significant events classified as Serious Adverse Reactions. These include episodes of severe hypotension (which can lead to shock or syncope) and the potential for a rare blood disorder, Methemoglobinemia.

Safety Restrictions and Special Populations

Official labeling defines specific conditions where the medicine must not be used (contraindications). This includes individuals with severe anemia or pre-existing conditions that cause increased intracranial pressure. A mandatory restriction is the absolute prohibition of concurrent use with Phosphodiesterase-5 (PDE-5) inhibitors due to the risk of life-threatening hypotension. Older adults are advised to use the medicine cautiously due to a potential increased sensitivity to hypotensive effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation defines the overdose profile of Nitrosan by describing severe systemic risks derived from its component agents.

Feature Official Regulatory Statements
Documented Manifestations: Profound Hypotension, Severe Pulsating Headache, Methemoglobinemia, Reflex Tachycardia, Syncope, Nausea and Vomiting, Flushing.
Life-Threatening Outcomes: Circulatory Collapse, Shock, Respiratory Depression, Increased Intracranial Pressure, Myocardial Ischemia.
Antidote Information: No specific antidote is known for general effects; Methylene Blue is documented for the complication Methemoglobinemia.
Required Emergency Action: Seek Immediate Medical Attention upon recognizing any sign of overdose.

The appearance of documented manifestations such as profound hypotension or syncope requires immediate attention, as these can lead to life-threatening outcomes including circulatory collapse and respiratory depression. The most critical officially listed complication is Methemoglobinemia, an impairment of systemic oxygen transport.

Regulatory guidelines mandate that users Seek Immediate Medical Attention if any signs of overdose are observed. In cases involving severe, life-threatening symptoms, official documents require users to Contact Emergency Services Immediately.

While no specific antidote is known for general overdose effects, management is described as symptomatic and supportive. Regulatory procedures for managing overdose may include Gastric Lavage and the required Administration of Methylene Blue when Methemoglobinemia is confirmed. Hospital Monitoring of vital signs and Arterial Blood Gas (ABG) Monitoring are required to track severity, as specified in official regulatory documents.

Therapeutic Uses of Nitrosan

What Nitrosan Treats: Main Uses and Benefits

Managing Symptoms Related to Acute and Chronic Anginal Episodes

This medication is commonly used to help manage symptoms related to acute episodes of anginal chest pain, a squeezing or pressure associated with acute or episodic changes. It is also relevant for managing symptoms associated with recurrent anginal episodes in chronic stable conditions. The nitroglycerin component is utilized in symptomatic management to help address an attack that is already occurring and to assist in reducing the potential for episodic manifestations. This approach helps ease the overall symptom burden, and supports patients in coping more steadily with difficult manifestations.

Supporting Management of Internal Helminthic Burdens

Nitrosan is considered relevant for managing conditions associated with confirmed parasitic infections involving susceptible intestinal worms (helminths). This is commonly used in scenarios where additional management of discomfort is required to address the biological stressors. It is used for managing these stressors, which is relevant for patients who may need simultaneous management of systemic symptoms and internal infection. This application contributes to easing the overall symptom load for patients during symptomatic phases.

Quick Fact: Relief for Angina and Parasite Burden
Main Symptom Domains Acute Chest Pain, Recurrent Anginal Episodes, Helminthic Infections, Localized Tension.
Common Scenario Often used during phases when symptoms become more noticeable, or when management of biological stressors is appropriate.
Core Benefit Supports general well-being during symptomatic phases and helps ease the overall symptom burden.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility profile for Nitrosan is based on the active ingredient Nitrazepam and is defined by strict regulatory criteria across age, reproductive status, and co-existing severe medical conditions.

Eligibility Status

Classification Populations that Must Not Use (Contraindicated)
Absolute Exclusion Patients with Severe hepatic insufficiency, Myasthenia gravis, Sleep apnoea syndrome, Acute pulmonary insufficiency, or Respiratory depression
Reproductive Exclusion Women who are pregnant (due to documented risk of congenital malformations) or are breastfeeding
Hypersensitivity Patients with known Hypersensitivity to benzodiazepines or any component of the formulation

Restricted or Conditional Use

Classification Populations with Special Considerations (Restricted Use)
Age Restriction Children (under 18 years) are not recommended to use this medicine; Elderly patients require a typically lower dose due to increased sensitivity and risk of falls
Organ Impairment Patients with chronic renal or hepatic disease must have a potentially reduced dose due to prolonged presence of the drug in the body
Other Restrictions Use requires caution and close monitoring for patients with a history of alcohol or drug abuse.

Regulatory documents establish that only adult patients without these specific contraindications or restrictive conditions may be considered eligible for treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Nitrosan is defined by specific drug-drug, drug-substance, and drug-food patterns documented in official regulatory labeling.

Formal Regulatory Prohibitions

The co-administration of Nitrosan is contraindicated with all Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil) and Soluble Guanylate Cyclase (sGC) Stimulators (e.g., riociguat). This prohibition is based on the documented risk of severe, life-threatening hypotension that results from the potentiation of vasodilatory effects.

Pharmacodynamic and Exposure Changes

Co-administration with Antihypertensive Drugs (including beta-blockers, phenothiazines, and calcium channel blockers) may cause additive hypotensive effects or marked orthostatic hypotension. The concurrent use of Alcohol (Ethanol) may similarly lead to documented hypotension. Aspirin is officially documented to potentially decrease the clearance of the cardiovascular component, which may enhance its hemodynamic effects. Use with Ergotamine is restricted due to the interaction resulting in increased bioavailability of Ergotamine. Use with long-acting nitrates may lead to a decrease in the therapeutic effect of Nitrosan's short-acting component due to cross-tolerance.

Food and Administration Timing

The efficacy of the Nitroscanate anti-parasitic component is officially affected by food. The regulatory text includes a mandatory requirement for the restriction or withholding of food intake at the time of administration to ensure optimal exposure for therapeutic effectiveness.

Mechanism of Action

How Nitrosan Works: Mechanism of Action

Enzymatic Bioactivation and Nitric Oxide Release

Nitrosan is an inactive prodrug that requires activation by the enzyme ALDH2 (Mitochondrial Aldehyde Dehydrogenase) within the vascular smooth muscle cells. This enzymatic process releases the gaseous signaling molecule Nitric Oxide ( NO), initiating the drug's downstream biological effects.

The NO- cGMP Vasodilation Pathway

The released NO acts as a modulator by binding to and activating soluble Guanylate Cyclase (sGC), an enzyme that synthesizes the critical second messenger, cyclic Guanosine Monophosphate ( cGMP). Elevated cGMP levels trigger a phosphorylation cascade that causes the relaxation of the vascular smooth muscle, resulting in vasodilation.

Modulating Cardiac Workload (Preload and Afterload)

This widespread vasodilation is a central physiological consequence. The relaxation of the venous system reduces the volume of blood returning to the heart (preload), while arterial dilation lowers the resistance against which the heart pumps (afterload). These systemic adjustments result in a decrease in myocardial oxygen demand and a reduction in the heart's overall workload.

Mechanism Limitations: Nitrate Tolerance

The mechanism's sustained activity is modulated by its reliance on the ALDH2 enzyme. Repeated exposure can lead to a reduction in the drug's effectiveness, known as nitrate tolerance, a phenomenon involving reduced bioactivation capacity due to changes in ALDH2 activity and potential oxidative changes in sGC sensitivity.

Dosage and Administration Information

This section summarizes the administration instructions for Nitrosan (Nitroglycerin).

Administration Scope

Feature General Instruction
Route of Administration Primarily Sublingual (under the tongue) for quick-acting forms; Oral for extended-release capsules; Transdermal (patch/ointment); Intravenous (IV solution).
Dosing Schedule Acute Use (Sublingual/Spray): One dose (e.g., 0.3 mg, 0.4 mg, or 1 spray) at the onset of an event. Dose may be repeated every 5 minutes as needed.
Maximum Frequency No more than three total doses (tablet/spray/packet) are recommended within a 15-minute period. If the issue persists, prompt medical attention is required.
Chronic Use Cycle Extended-release products (capsules, patches) require a daily nitrate-free interval (typically 10–12 hours) to avoid tolerance.
Age-Group Rules Geriatric Use: The smallest effective dose is recommended. Pediatric Use: Safety and dose are generally not established and must be determined by a healthcare provider.

Special Procedural Conditions

Condition Guideline Details
Intake Method Sublingual tablets/powder must be allowed to dissolve completely under the tongue or in the cheek pouch; they must not be swallowed, chewed, or crushed.
Intake Position Acute doses should be administered while the patient is at rest, preferably in the sitting position.
Preparation Lingual spray devices must be primed (e.g., test sprays into the air) before first use or if not used for a specific duration.
IV Dilution Intravenous concentrate must be diluted in Dextrose 5% or Sodium Chloride 0.9% and should be administered using glass bottles or non-absorptive tubing to prevent drug loss.

Connection to the Overall Use Protocol

These administration guidelines define the appropriate use of the medicine across its different forms, distinguishing between the time-critical, as-needed dosing for acute events and the scheduled, interval-based regimens for sustained use. The protocol mandates specific routes and procedural steps, such as dissolving tablets rather than swallowing them, and enforces limits on repeated acute doses to guide patient management.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Evaluating the Research Focus of Nitrosan

Research has explored how the combination treatment may be linked to changes in reported pain severity, and evaluated whether it may be associated with changes in patient mobility and quality of life measures. The majority of studies evaluated the effect on patients diagnosed with chronic, moderate-to-severe pain. Consultation with a physician can provide context regarding whether this drug combination has been evaluated for specific patient conditions.

Key Findings from Clinical Trials

Phase 3 trials have been conducted to evaluate the potential effects of Nitrosan. These trials focused on measuring changes in a patient-reported pain score, such as the Visual Analog Scale (VAS), over a 12-week period.

  • A key study examined whether the drug combination may be linked to changes in symptoms over a short timeframe, specifically tracking patient responses during the initial 48 hours of treatment.
  • The primary endpoint of the pivotal trial was a 30% or greater change in the VAS pain score from baseline to week 12. The study reported that a specified percentage of participants met this predefined criterion compared to those receiving placebo.
  • Research explored differences in the proportion of participants meeting response criteria when the two agents were combined versus when each agent was examined separately.

Data on Participant Experience and Long-Term Evaluation

Studies have also tracked the adverse events and tolerability of Nitrosan during trials.

  • Adverse events reported during the clinical trials were generally consistent with the known side-effect profiles of the individual components of the drug combination.
  • Furthermore, long-term studies tracked the experience of the drug combination by participants, and research has evaluated data for potential differences in the rate of disease progression in certain subgroups.
  • This data describes the findings of using this drug. It is not yet clear whether these long-term observations are directly attributable to the treatment or other factors.

How should Nitrosan be stored and disposed of?

How to Store and Dispose of Nitrosan

Nitrosan must be stored according to specific regulatory requirements to maintain its stability and potency.

Official Storage Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Container Keep in the original glass container with a tightly sealed cap.
Protection Must be protected from light and humidity; keep the container tightly capped immediately after use.
Child Safety Store out of the sight and reach of children.

Disposal Instructions

Unused or expired Nitrosan should be disposed of via an authorized drug take-back program. If a take-back option is unavailable, the product may be mixed with an undesirable substance (such as dirt) and sealed in a container before being placed in the household trash. The medication must not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nitrosan found in:

A-Z Index: